Amneal Pharmaceuticals Free Cash Flow (FCF) History (AMRX)

Amneal Pharmaceuticals reported $269.9M in free cash flow for fiscal 2025, an increase of 11.00% from the previous fiscal year, with a free cash flow margin of 8.94%.

View full Amneal Pharmaceuticals company overview

Amneal Pharmaceuticals free cash flow by year

Amneal Pharmaceuticals annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31$269.9M$26.8M+11.00%+8.94%
20242024-12-31$243.2M−$59.2M−19.57%+8.70%
20232023-12-31$302.4M$283.7M+1517.51%+12.63%
20222022-12-31$18.7M−$175.4M−90.37%+0.84%
20212021-12-31$194.1M−$128.5M−39.83%+9.27%
20202020-12-31$322.6M$368.0M+16.19%
20192019-12-31−$45.5M−$212.6M−2.80%
20182018-12-31$167.1M$27.7M+19.89%+10.05%
20172017-12-31$139.4M$147.1M+13.49%
20162016-12-31−$7.7M−0.76%

Amneal Pharmaceuticals free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from $322.6M to $269.9M, a compound annual decline of 3.50%. Amneal Pharmaceuticals's latest reported quarter, Q2 2026, generated −$51.9M in free cash flow, a decrease of $112.9M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Amneal Pharmaceuticals filings at SEC.gov ↗